G. Walsh

发表

Adjuvant chemotherapy for breast cancer: side effects and quality of life.

J. Mckinna, W. P. Greening, B. Palmer, 1980, British medical journal.

High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer.

B. Gusterson, S. Ebbs, S. Johnston, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemotherapy for breast cancer: side effects and quality of life.

J. Mckinna, W. P. Greening, B. Palmer, 1980 .

Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: menstruation and pregnancy outcomes.

I. Smith, G. Walsh, S. O'neill, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC)

M. Dowsett, A. Urruticoechea, I. Smith, 2008, Breast Cancer Research and Treatment.

Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer

L. Assersohn, S. Johnston, A. Urruticoechea, 2005, British Journal of Cancer.

Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.

M. Dowsett, S. Ebbs, J. Salter, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of timing of adjuvant chemotherapy for early breast cancer: the Royal Marsden Hospital experience

S. Johnston, I. Smith, N. Turner, 2021, British Journal of Cancer.

Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab

C. Swanton, T. Yau, S. Johnston, 2006, Acta oncologica.

Occult primary breast carcinoma presenting as axillary lymphadenopathy.

I. Smith, R. A’Hern, G. Walsh, 2002, Breast.

Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial.

A. Harris, I. Smith, J. Gazet, 1981, British medical journal.

Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma

I. Smith, A. Ring, R. Jones, 2006, British Journal of Cancer.

Factors determining outcome after third line chemotherapy for metastatic breast cancer.

S. Johnston, U. Banerji, I. Smith, 2007, Breast.

Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer.

P. Ellis, S. Johnston, I. Smith, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen.

D. Talbot, I. Smith, A. Jones, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patterns of breast relapse after local excision +/- radiotherapy for early stage breast cancer.

J. Yarnold, P. Price, G. Walsh, 1988, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Inflammatory breast cancer—The Royal Marsden Hospital experience

S. Johnston, I. Smith, G. Walsh, 2010, Cancer.

Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.

P. Lønning, M. Dowsett, D. Hayes, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multimodality therapy in inflammatory breast cancer: is there a place for surgery?

S. Ebbs, S. Johnston, I. Smith, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy

M. Dowsett, P. Ellis, J. Salter, 1998, Breast Cancer Research and Treatment.

Proliferation and Apoptosis as Markers of Benefit in Neoadjuvant Endocrine Therapy of Breast Cancer

M. Dowsett, S. Ebbs, J. Salter, 2006, Clinical Cancer Research.

Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer?

W. Allum, I. Smith, A. Ring, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Duct carcinoma in situ: predictors of local recurrence and progression in patients treated by surgery alone.

B. Gusterson, R. A’Hern, J. Mckinna, 1990, British Journal of Cancer.

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.

M. Dowsett, S. Ebbs, J. Blohmer, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer--how low can you go?

S. Johnston, U. Banerji, I. Smith, 2007, Breast.

Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.

Mitch Dowsett, Roger A'Hern, M. Dowsett, 2007, Journal of the National Cancer Institute.

A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.

M. Dowsett, J. Mayordomo, J. Salter, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer

S. Johnston, M. O'Brien, R. Jones, 2009, British Journal of Cancer.

Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.

M. Dowsett, S. Ebbs, J. Salter, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Platinum-based chemotherapy in triple-negative breast cancer.

S. Johnston, I. Smith, B. Sirohi, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

The early diagnosis of breast cancer--a twenty-year experience at the Royal Marsden Hospital.

J. Davey, R. A’Hern, J. Mckinna, 1992, European journal of cancer.

Is Capecitabine Efficacious in Triple Negative Metastatic Breast Cancer?

S. Johnston, I. Smith, G. Walsh, 2011, Oncology.

Primary medical therapy for operable breast cancer.

J A McKinna, P A Trott, C. Fisher, 1989, European journal of cancer & clinical oncology.

The role of ipsilateral breast radiotherapy in management of occult primary breast cancer presenting as axillary lymphadenopathy.

I. Smith, A. Kirby, G. Walsh, 2011, European journal of cancer.

celecoxib in patients with primary breast cancer

M. Dowsett, J. Salter, M. Weigel, 2011 .

Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer

M. Dowsett, J. Salter, R. A’Hern, 2010, Breast Cancer Research and Treatment.

A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer.

I. Smith, D. Jodrell, J. Mckinna, 1991, British Journal of Cancer.

A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer.

P. Ellis, S. Johnston, I. Smith, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab.

I. Smith, B. Yeo, G. Walsh, 2015, Breast.

The incidence of breast cancer from screening women according to predicted family history risk: Does annual clinical examination add to mammography?

R. A’Hern, G. Walsh, R. Eeles, 2001, European journal of cancer.

Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer.

P. Ellis, S. Ebbs, M. Baum, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Is S urgery N ecessary A fter C omplete C linical R emission Following N eoadjuvant C hemotherapy f or E arly B reast C ancer

S. Ebbs, I. Smith, G. Gui, 2003 .

Ductcarcinoma insitu: predictors oflocal recurrenceandprogression in patients treated bysurgeryalone

B. Gusterson, R. A’Hern, J. Mckinna, 1990 .

Continuous infusional combination chemotherapy in inflammatory breast cancer: a phase II study.

P. Ellis, S. Johnston, I. Smith, 2000, Breast.

Ultrasound assessment of residual abnormalities following primary chemotherapy for breast cancer.

I. Smith, E. Moskovic, M. Seymour, 1997, British Journal of Cancer.

471 Capecitabine in older patients ⩾70 yrs with locally advanced or metastatic breast cancer

I. Smith, G. Walsh, S. Ashley, 2010 .

The role of ipsilateral breast radiotherapy in management of occult primary breast cancer presenting as axillary lymphadenopathy.

I. Smith, A. Kirby, G. Walsh, 2011, European journal of cancer.

A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer.

H. Sinnett, J. Mansi, G. Walsh, 1991, British Journal of Cancer.

A study of factors determining outcome of patients receiving third line chemotherapy for metastatic breast cancer: The Royal Marsden Hospital experience.

S. Johnston, U. Banerji, I. Smith, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary medical chemotherapy with continuous infusional 5-fu (F), epirubicin (E) and cisplatin (P) for large operable breast cancer: a very active new regimen

S. Ebbs, M. Baum, I. Smith, 1993 .